OncoResponse
909 Fannin Street
Suite 2100
Houston
Texas
77024
United States
Tel: 206-805-1600
Fax: 206-805-1699
Website: http://www.oncoresponseinc.com/
Email: info@oncoresponseinc.com
About OncoResponse
OncoResponse, a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.
OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer, thereby extending the benefit of immunotherapy to a greater number of patients.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Clifford J. Stocks
CSO: Kristine Swiderek, Ph.D.
CFO: Russ Hawkinson
TECHNOLOGY:
Please click here for OncoResponse's technology.
8 articles with OncoResponse
-
April springs up with showers of cash for these life sciences companies.
-
OncoResponse Raises $40.6 Million Series C Financing
3/31/2021
- New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies - Adds Magnetar Group, Yonjin Ventures and Bering Capital to the syndicate
-
OncoResponse Raises $40 Million in Series B Financing
9/11/2018
Adds RiverVest Venture Partners, Qatar Investment Authority and Redmile Group to List of Financial Backers
-
OncoResponse Expands Scientific Leadership With the Addition of Dr. Anil Singhal as CSO and Dr. Kamal D. Puri as VP, R&D
1/2/2018
OncoResponse today announced it has expanded its scientific leadership through the additions of Anil Singhal, Ph.D., and Kamal D. Puri, Ph.D., to the management team.
-
OncoResponse Adds Anti-EMP2 Antibody to Oncology Pipeline Through Acquisition of Paganini Biopharma
11/7/2017
OncoResponse today announced that it has closed the acquisition of Paganini Biopharma, acquiring all of its assets including an anti-epithelial membrane protein 2 (EMP2) fully human monoclonal antibody, ONCR-201.
-
OncoResponse Announces Final Closing Of $22.5M Series A Financing Round
3/9/2017
-
OncoResponse Secures $7 Million In Supplemental Series A Funding
10/10/2016
-
Helsinn Investment Fund To Invest $3.5 Million In OncoResponse
10/10/2016